Se connecter

Bibliographies thématiques / Bureau for the aged / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Bureau for the aged.

Articles de revues sur le sujet « Bureau for the aged »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 29 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Bureau for the aged ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Matsuda, Kensuke, Taisuke Jo, Arika Nukina Shimura, et al. "Risk of Febrile Neutropenia in Very Elderly Patients Aged ≥80 Years Who Received R-CHOP Regimen: A Nationwide Analysis in Japan." Blood 138, Supplement 1 (2021): 2530. http://dx.doi.org/10.1182/blood-2021-144998.

Texte intégral

Résumé :

Abstract Background: Despite the aging society, few studies have evaluated risk factors for febrile neutropenia (FN) in the very elderly. This may be due to the difficulty of conducting a prospective study in the presence of comorbidities and a limited number of patients. We retrospectively analyzed risk factors for FN in the first cycle of rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP) regimen in the very elderly aged ≥ 80 years using a nationwide inpatient database in Japan. Study Design and Methods: This study was a retrospective cohort study using the Diagnosis Pr

Styles APA, Harvard, Vancouver, ISO, etc.

2

Larocca, Alessandra, Paul G. Richardson, Albert Oriol, et al. "HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients." Blood 136, Supplement 1 (2020): 44–46. http://dx.doi.org/10.1182/blood-2020-136856.

Texte intégral

Résumé :

Background: Advances in therapy have improved outcomes in multiple myeloma (MM), but enhancement in overall survival (OS) has resulted in patients living with the burden of symptoms and complications of relapsed/refractory MM (RRMM) and prior lines of therapy (Vogl et al. Leuk Lymphoma. 2018;59:398; Kumar et al. Leukemia. 2017;31:2443). Elderly patients represent a particularly difficult-to-treat population with RRMM due to the additional presence of comorbidities, reduced fitness level, and treatment with concomitant medications (Larocca et al. Leukemia. 2018;32:1697). There is an unmet need

Styles APA, Harvard, Vancouver, ISO, etc.

3

Chen, Shulin, Lisa L. Boyle, Yeates Conwell, Shuiyuan Xiao, and Helen Fung Kum Chiu. "The challenges of dementia care in rural China." International Psychogeriatrics 26, no. 7 (2014): 1059–64. http://dx.doi.org/10.1017/s1041610214000854.

Texte intégral

Résumé :

Many countries face policy challenges related to the well-being of their aging populations, and China, with the world's largest aging population, is no different. Over the past 40 years, China has experienced demographic transition toward an “aging society.” According to the National Bureau of Statistics in China (NBSC), the number of people aged 60 years and older in China has risen to 185 million, with rural areas aging more rapidly during China's demographic transition (National Bureau of Statistics of China, 2013). In 1982, the proportion of population aged 60 years and older was 7.8% in r

Styles APA, Harvard, Vancouver, ISO, etc.

4

Peyvandi, Flora, Bruce A. Schwartz, and Sigurd Knaub. "Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency." Blood 132, Supplement 1 (2018): 2501. http://dx.doi.org/10.1182/blood-2018-99-116572.

Texte intégral

Résumé :

Abstract Introduction: Individuals with congenital afibrinogenemia can experience frequent and/or severe bleeding episodes (BE). Human fibrinogen concentrate (HFC) can correct the hemostatic defect and arrest bleeding. We investigated the efficacy, safety and pharmacokinetics (PK) of a new highly purified, double virus-inactivated HFC (Fibryga, Octapharma) in adolescent patients. Methods: Data were analyzed from two multinational, prospective, open-label studies. FORMA-01 studied the PK of the new HFC vs. comparator (Haemocomplettan P), as well as surrogate efficacy and safety, after single in

Styles APA, Harvard, Vancouver, ISO, etc.

5

Van Anglen, Lucinda J., Richard M. Mandel, Ramesh V. Nathan, et al. "Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population." Open Forum Infectious Diseases 4, suppl_1 (2017): S331—S332. http://dx.doi.org/10.1093/ofid/ofx163.785.

Texte intégral

Résumé :

Abstract Background The aged population (≥75 years) have multiple comorbidities and are at increased risk of adverse events associated with intravenous antimicrobial therapy. Hospitalization (hosp) occurs frequently. This group presents challenges for site of care and reimbursement, which may be met with provision of OPAT through a physician office infusion center (POIC). This setting allows treatment immediately following hosp or directly from the community, thus avoiding hosp. For the aged patient (pt) population, we evaluated safety and effectiveness of OPAT in a POIC. Methods Records from

Styles APA, Harvard, Vancouver, ISO, etc.

6

Weller, Jan Frederic, Louisa Kaufmann, Claudia Lengerke, et al. "Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)." Blood 138, Supplement 1 (2021): 3926. http://dx.doi.org/10.1182/blood-2021-152349.

Texte intégral

Résumé :

Abstract Introduction. Malignant diseases treated with allogeneic hematopoietic stem cell transplantation (alloHSCT) predominantly occur beyond the 7 th decade of life. Numerical age per se is not regarded an adverse risk factor in alloHSCT. In an aging society, interventions historically deemed high risk are increasingly used in elder patients. Methods. Epidemiology, outcomes and risk factors of patients aged ≥70 years undergoing alloHSCT in Germany 1999-2019 and registered with the DRST/EBMT database were analyzed retrospectively. Baseline patient, disease, and transplant data were collected

Styles APA, Harvard, Vancouver, ISO, etc.

7

Young, Guy, Robert F. Sidonio, Ri Liesner, et al. "HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors." Blood 130, Suppl_1 (2017): 85. http://dx.doi.org/10.1182/blood.v130.suppl_1.85.85.

Texte intégral

Résumé :

Abstract Introduction Emicizumab, a bispecific humanized monoclonal antibody administered subcutaneously, bridges FIXa and FX to restore the function of missing FVIIIa, and is being developed to prevent bleeds in patients with hemophilia A (PwHA) with and without inhibitors. An interim analysis of the HAVEN 2 study (n=20) in patients aged 2-12 years (data cutoff 28 Oct, 2016) showed that subcutaneous, once-weekly emicizumab prophylaxis successfully prevented or reduced bleeds, provided clinically meaningful reductions in annualized bleed rate (ABR) versus prior bypassing agent (BPA) treatment,

Styles APA, Harvard, Vancouver, ISO, etc.

8

Tsakiris, Dimitrios A., Johannes Oldenburg, Robert Klamroth, et al. "Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies." Blood 136, Supplement 1 (2020): 1. http://dx.doi.org/10.1182/blood-2020-139873.

Texte intégral

Résumé :

Introduction: Long-term effectiveness and safety data in patients treated in routine clinical practice settings can be captured from real-world studies. The international (INT) and German (GER) Antihemophilic factor (recombinant; rAHF) Hemophilia A (HA) outcome Database (AHEAD) studies assess long-term effectiveness and safety outcomes in patients with moderate HA (factor VIII level 1-5%) or severe HA (factor VIII &lt;1%) receiving rAHF (ADVATE®; Baxalta US Inc., a Takeda company, Lexington, MA, USA) in routine clinical practice. Methods: These are non-interventional, prospective, long-ter

Styles APA, Harvard, Vancouver, ISO, etc.

9

Jiménez-Yuste, Víctor, Johannes Oldenburg, Eunice Tzeng, Ben Trzaskoma, Fabian Sanabria, and Johnny Mahlangu. "Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY)." Blood 138, Supplement 1 (2021): 2103. http://dx.doi.org/10.1182/blood-2021-145703.

Texte intégral

Résumé :

Abstract Background: Emicizumab is indicated for prophylaxis in persons with hemophilia A (PwHA) of all ages, with/without factor (F)VIII inhibitors (exact label may vary by country). For older persons receiving emicizumab, however, their care may be complicated by comorbidities. Prevalence and early onset of cardiovascular (CV) risk factors, including hypertension, are common among PwHA (Humphries, et al. Adv Med Sci 2018; Sood, et al. Blood Adv 2018). Human immunodeficiency virus (HIV), which is likely to be more common in older PwHA, is associated with increased risk of heart disease (Shah,

Styles APA, Harvard, Vancouver, ISO, etc.

10

Siegel, David S., Gary Schiller, Kevin Song, et al. "Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)." Blood 126, no. 23 (2015): 1853. http://dx.doi.org/10.1182/blood.v126.23.1853.1853.

Texte intégral

Résumé :

Abstract Background: Preclinical studies indicate that lenalidomide (LEN) and POM are not cross-resistant (Ocio et al Leukemia, 2015) and that POM remains active in LEN-resistant myeloma cells (Lopez-Girona et al Leukemia, 2012). Likewise, POM + LoDEX showed comparable efficacy in patients (pts) refractory to LEN administered as last prior Tx vs the full population in subanalyses of the clinical trials MM-002 and MM-003 (San Miguel et al Lancet Oncol, 2013; Richardson et al Blood, 2014). To confirm these observations, we initiated a single-arm, phase 2 trial evaluating POM + LoDEX immediately

Styles APA, Harvard, Vancouver, ISO, etc.

11

Hampton, Kingsley, Pratima Chowdary, Scott Dunkley, et al. "First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a." Blood 126, no. 23 (2015): 2283. http://dx.doi.org/10.1182/blood.v126.23.2283.2283.

Texte intégral

Résumé :

Abstract Introduction N8-GP (turoctocog alfa pegol) is an extended half-life, recombinant factor VIII (FVIII) that has a site-specific glycoPEGylation in the truncated B-domain. Upon activation, the glycopegylated domain is cleaved from N8-GP yielding FVIIIa, which is identical to endogenous FVIIIa. PathfinderTM 2 and pathfinder™3 (www.ClinicalTrials.gov identifiers: NCT01480180 and NCT01489111, respectively) are ongoing international, open-label, non-randomized, phase 3 clinical trials of N8-GP in patients aged ≥12 years with severe hemophilia A and with a documented history of at least 150 e

Styles APA, Harvard, Vancouver, ISO, etc.

12

Berdeja, Jesus G., Noopur S. Raje, David S. Siegel, et al. "Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis." Blood 136, Supplement 1 (2020): 16–17. http://dx.doi.org/10.1182/blood-2020-134322.

Texte intégral

Résumé :

Background: Multiple myeloma (MM) occurs most commonly among the older population, with a median age of 69 years at diagnosis. Advanced age has been shown to negatively affect prognosis and limit treatment options for patients with hematologic malignancies, including MM. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, demonstrated deep and durable responses in the pivotal phase 2 KarMMa study of patients with triple-class exposed relapsed and refractory MM (RRMM; Munshi et al. J Clin Oncol. 2020;38[suppl, abstr]:8503). The overall response rate (ORR), complete res

Styles APA, Harvard, Vancouver, ISO, etc.

13

Rebollo Giménez, A. I., L. Sacristán-Bou, D. Bellido Pastrana, et al. "AB1281 PRESENTATION, TREATMENT AND PROGNOSIS OF SARCOIDOSIS IN A COHORT OF SPANISH PATIENTS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1748.1–1748. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1412.

Texte intégral

Résumé :

BackgroundSarcoidosis is usually a benign disease, but it is described that the lung is the most frequently affected organ and in some cases the disease can progress to pulmonary fibrosis. Systemic corticosteroids, immunosuppressants and/or monoclonal antibodies are used for its treatment. The mortality rate without treatment is 1% to 6%.ObjectivesTo establish the frequency of appearance of the stages of radiological involvement in patients diagnosed with sarcoidosis at Ciudad Real University General Hospital (CRUGH) for 4 years, describe the treatment guidelines used and investigate the cause

Styles APA, Harvard, Vancouver, ISO, etc.

14

Tchernev, Georgi, Hristo Mangarov, Ilia Lozev, et al. "Acquired Ulcero-Mutilating Bilateral Acro-Osteopathy (Bureau-Barrière Syndrome)." Open Access Macedonian Journal of Medical Sciences 5, no. 4 (2017): 558–60. http://dx.doi.org/10.3889/oamjms.2017.134.

Texte intégral

Résumé :

We present a 35-year-old male patient with Bureau-Barrière syndrome. Bureau-Barrière syndrome is an ulcero-mutilating acropathy almost invariably associated with excessive alcohol intake. It presents with a triad of trophic skin changes with recurrent ulcerations, bone lesions and nerve damage. The clinical presentation includes chronic painless plantar ulcerations with periulcerous hyperkeratosis, hyperhidrosis, livedoid skin colour, nail dystrophy, widening and infiltration of the toes and common interdigital mycoses. Other non-specific skin changes related to the alcohol consumption are com

Styles APA, Harvard, Vancouver, ISO, etc.

15

Giebel, Sebastian, Myriam Labopin, Mohamed Houhou, et al. "Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation." Blood 136, Supplement 1 (2020): 6–7. http://dx.doi.org/10.1182/blood-2020-140328.

Texte intégral

Résumé :

BACKGROUND: The outcome of patients with acute lymphoblastic leukemia (ALL) aged above 55 years treated with conventional-dose chemotherapy is poor. Due to the frequent presence of co-morbidities many patients are ineligible for myeloablative allogeneic (allo) hematopoietic cell transplantation (HCT). The role of autologous (auto) HCT and reduced intensity conditioning (RIC)-alloHCT is not well-established. The goal of this study was to analyze results of these transplant options and to identify factors affecting outcome. PATIENTS: Five-hundred and sixty patients with ALL treated in first comp

Styles APA, Harvard, Vancouver, ISO, etc.

16

Simon, Florian, Adam Giza, Sandra Robrecht, et al. "Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older." Blood 138, Supplement 1 (2021): 1552. http://dx.doi.org/10.1182/blood-2021-150698.

Texte intégral

Résumé :

Abstract Background: Patients (pts) aged 80 years or older, albeit making up ≥ 20% of CLL pts, are still underrepresented in clinical trials and treatment outcomes in this cohort remain understudied. We conducted an analysis of pts aged 80 years or older in 6 phase II and III studies of the German CLL Study Group (GCLLSG) in the frontline-setting to elucidate outcomes of targeted treatments with regard to relevant clinical endpoints including overall survival and causes of death. Methods: We pooled data of pts aged 80 years or older at the time of first-line treatment, with at least one admini

Styles APA, Harvard, Vancouver, ISO, etc.

17

Crosswell, Howland E., Ann S. LaCasce, Nancy L. Bartlett, et al. "Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study." Blood 132, Supplement 1 (2018): 1647. http://dx.doi.org/10.1182/blood-2018-99-112907.

Texte intégral

Résumé :

Abstract Introduction: Hodgkin lymphoma (HL) is a rare disease that commonly occurs in AYAs, defined in the United States as patients 15 to 39 years of age. Brentuximab vedotin (Adcetris®; A) is an anti-CD30 antibody-drug conjugate approved for adult patients with previously untreated stage III or IV classical HL (cHL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy based on results from the phase 3 ECHELON-1 trial which demonstrated a significantly improved modified progression-free survival (mPFS) compared with doxorubicin, bleomycin, vinblastine, and dacarbaz

Styles APA, Harvard, Vancouver, ISO, etc.

18

Guiñazú, Javier Ruiz, Jelena Tica, Charles P. Andrews, et al. "121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic." Open Forum Infectious Diseases 7, Supplement_1 (2020): S188—S189. http://dx.doi.org/10.1093/ofid/ofaa439.431.

Texte intégral

Résumé :

Abstract Background RSV causes significant disease burden in older adults, since reinfections are common and may lead to severe disease presentations while only supportive treatment is available. We present immunogenicity of different formulations of an investigational vaccine (RSVPreF3) in young and older adults. Methods This is a phase I/II, placebo-controlled, multi-country trial (NCT03814590). Healthy adults aged 18–40 years were randomized 1:1:1:1 to receive 2 doses of either Low-, Medium- or High-dose of RSVPreF3 non-adjuvanted vaccine or placebo, 2 months apart. Following favorable safe

Styles APA, Harvard, Vancouver, ISO, etc.

19

Buch, M. H., J. A. Gómez-Puerta, G. R. Burmester, et al. "POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 397.1–398. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1552.

Texte intégral

Résumé :

BackgroundFIL is an oral Janus kinase 1 preferential inhibitor for the treatment of moderate to severe active RA. A previous pooled analysis reported long-term safety and efficacy for FIL 200 mg (FIL200) vs FIL 100 mg (FIL100) in pts aged ≥65 and <65 y.[1]ObjectivesTo report updated long-term safety and efficacy in 4 subgroups of pts with RA (aged <65 y, ≥65 y, <65 y without CV risk, and ≥65 y or with CV risk), treated with FIL200 vs FIL100.MethodsThispost hocanalysis pooled data from phase 2 (DARWIN 1–3;NCT01888874,NCT01894516,NCT02065700) and phase 3 (FINCH 1–4;NCT02889796,NCT028739

Styles APA, Harvard, Vancouver, ISO, etc.

20

Caimi, Paolo F., Weiyun Z. Ai, Juan Pablo Alderuccio, et al. "Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (2020): 35–37. http://dx.doi.org/10.1182/blood-2020-137524.

Texte intégral

Résumé :

Introduction: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who fail multi-agent chemoimmunotherapy have a poor prognosis and a need for more treatment options. Loncastuximab tesirine (Lonca) comprises a humanized anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer toxin. We present updated results from a phase 2 study of Lonca in patients with R/R DLBCL who had failed established therapies, including analysis of response in high-risk DLBCL subgroups. Methods: Patients aged ≥18 years with R/R DLBCL who had failed ≥2 prior therapies were enro

Styles APA, Harvard, Vancouver, ISO, etc.

21

Rosati, Serena, Massimo Breccia, Carmelo Gurnari, et al. "Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols." Blood 134, Supplement_1 (2019): 3845. http://dx.doi.org/10.1182/blood-2019-129216.

Texte intégral

Résumé :

Introduction APL in the elderly is rare and about 5% of patients with APL are older than 70 years at diagnosis; compared to young adults, prognosis of older patients with APL remains poorer, due to the presence of severe comorbidities and the higher rate of mortality related to induction or consolidation therapy. Aim To evaluate in an unselected real-life cohort of APL patients aged ≥ 70 years the true efficacy of targeted treatments and follow-up of disease. Methods A retrospective cohort of 45 consecutive APL patients (M/F 27/18), aged ≥ 70 years and diagnosed at 8 different hematologic inst

Styles APA, Harvard, Vancouver, ISO, etc.

22

McMillan, Andrew, Alejandro Martín, Corinne Haioun, et al. "Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma." Blood 128, no. 22 (2016): 4204. http://dx.doi.org/10.1182/blood.v128.22.4204.4204.

Texte intégral

Résumé :

Abstract INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most frequently observed hematologic malignancy with 45,000 patients newly diagnosed globally each year. DLBCL patients can be cured if successfully treated with first line therapy, but patients who relapse face a poor prognosis. OBJECTIVES: The aim of this analysis was to assess the prognosis for patients who relapse after first line treatment and to assess the impact of patient age on outcomes through a systematic review of the literature. METHODS: A systematic review of observational and interventional studies that describe

Styles APA, Harvard, Vancouver, ISO, etc.

23

Latagliata, Roberto, Daniela Bartoletti, Alessandro Andriani, et al. "Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea." Blood 138, Supplement 1 (2021): 2581. http://dx.doi.org/10.1182/blood-2021-149612.

Texte intégral

Résumé :

Abstract Introduction: Ruxolitinib (Rux) has been recently approved as second-line therapy in patients (pts) with Polycythemia Vera (PV) resistant/intolerant to hydroxyurea (HU). Median age of PV pts enrolled in the pivotal Response trials was around 60 yrs; at present, no data is reported on the use of Rux in elderly pts. Aims: In a real-world cohort of PV pts treated with Rux, we investigated whether the efficacy and safety of Rux were comparable in pts who initiated therapy when aged ≥75 years compared with younger pts. Methods: After IRB approval, clinical/laboratory data of 934 WHO2016-de

Styles APA, Harvard, Vancouver, ISO, etc.

24

Casulo, Carla, Michelle Byrtek, Keith L. Dawson, et al. "Disease Characteristics, Treatment Patterns, and Outcomes of Follicular Lymphoma in Patients 40 Years of Age and Younger: An Analysis from the National LymphoCare Study." Blood 124, no. 21 (2014): 3044. http://dx.doi.org/10.1182/blood.v124.21.3044.3044.

Texte intégral

Résumé :

Abstract Introduction: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the world and has a median age at diagnosis in the seventh decade. FL in young adults (YA; 40 years old or younger) is extremely rare. Currently, there are no standard approaches guiding treatment of YA patients with FL, and very little is known about disease characteristics and outcomes of YA patients with FL given limited research conducted in this vulnerable population. To gain further insight into FL in YA, we analyzed the National LymphoCare Study (NLCS) to describe disease and patient char

Styles APA, Harvard, Vancouver, ISO, etc.

25

Kulasekararaj, Austin G., Antonio Risitano, Alexander Roeth, et al. "Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy." Blood 138, Supplement 1 (2021): 4313. http://dx.doi.org/10.1182/blood-2021-152306.

Texte intégral

Résumé :

Abstract Background Crovalimab is a novel anti-complement C5 antibody currently being studied as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening disease associated with hemolytic anemia and thrombosis. Treatment with approved C5 inhibitors eculizumab or ravulizumab is effective, but can be limited by breakthrough hemolysis due to unsustained C5 inhibition, inadequate efficacy in patients with C5 mutational variants, and the requirement of regular intravenous infusions. Crovalimab is unique in that its properties allow for subcutaneous injections once every 4 weeks

Styles APA, Harvard, Vancouver, ISO, etc.

26

Dong, Ning, David S. Siegel, Phyllis McKiernan, et al. "Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients." Blood 132, Supplement 1 (2018): 4554. http://dx.doi.org/10.1182/blood-2018-99-117498.

Texte intégral

Résumé :

Abstract Background: Autologous stem cell transplantation (ASCT) is increasingly offered to older patients with multiple myeloma (MM) based on clinical trials demonstrating improved outcome. Inherently, successful mobilization and collection of peripheral blood stem cells (PBSC) is necessary for ASCT. A direct comparison of the efficacy of mobilization between elderly and younger patients has not been reported. Retrospective studies demonstrated that older patients had lower CD34+ cell yield and a higher incidence of mobilization failure (Lee et al 2014, Muchtar et al 2016). In this retrospect

Styles APA, Harvard, Vancouver, ISO, etc.

27

Peffault De Latour, Regis, Jeffrey Szer, Austin Kulasekararaj, et al. "Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies." Blood 136, Supplement 1 (2020): 42–43. http://dx.doi.org/10.1182/blood-2020-140777.

Texte intégral

Résumé :

Background: In the two largest phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH), ravulizumab given every 8 weeks was noninferior to eculizumab given every 2 weeks across all efficacy endpoints. Data on efficacy and safety of ravulizumab in patients aged &gt;65 years with PNH are limited. Aims: To compare the efficacy and safety of ravulizumab in patients with PNH aged &gt;65 years with those aged ≤65 years. Methods: The population included patients from two phase 3 studies that assessed ravulizumab vs eculizumab in complement-inhibitor-naïve (301; NCT02946463)

Styles APA, Harvard, Vancouver, ISO, etc.

28

Oldenburg, Johannes, María Teresa Alvarez Román, Giancarlo Castaman, et al. "Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study." Blood 134, Supplement_1 (2019): 4943. http://dx.doi.org/10.1182/blood-2019-128140.

Texte intégral

Résumé :

Background and Rationale: BAY 94-9027 (damoctocog alfa pegol) is a site-specifically PEGylated B-domain deleted recombinant factor VIII (FVIII) with an extended half-life, approved for prophylaxis or treatment of bleeds in previously treated patients (PTPs) aged ≥12 with hemophilia A. The efficacy and safety of BAY 94-9027 was demonstrated in two phase II/III clinical studies in PTPs with severe hemophilia A, however, real-world data are still being gathered. The aim of the HEM-POWR study is to assess the effectiveness and long-term safety of BAY 94-9027 in the real-world clinical setting. Pat

Styles APA, Harvard, Vancouver, ISO, etc.

29

Rifkin, Robert M., Stephen J. Noga, Saulius K. Girnius, et al. "Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation." Blood 138, Supplement 1 (2021): 2726. http://dx.doi.org/10.1182/blood-2021-150094.

Texte intégral

Résumé :

Abstract Background: Use of long-term PI-based therapy can improve outcomes across treatment settings in MM. However, there are various physical, geographical, and/or socioeconomic barriers to prolonged therapy with parenteral PIs in community practice. The US MM-6 study (NCT03173092) is assessing in-class transition (iCT) from parenteral bortezomib (V)-based induction to all-oral ixazomib-based therapy with ixazomib-lenalidomide-dexamethasone (IRd) in the diverse US community population. The objective of the study is to increase the duration of PI-based treatment, while maintaining quality of

Styles APA, Harvard, Vancouver, ISO, etc.

30

McLaughlin, Paul, Cedric Hermans, Sohaib Asghar, et al. "Problem Joints and Their Clinical and Humanistic Burden in Children and Adults with Moderate and Severe Hemophilia a: CHESS Paediatrics and CHESS II." Blood 136, Supplement 1 (2020): 33–34. http://dx.doi.org/10.1182/blood-2020-140306.

Texte intégral

Résumé :

Introduction Severe hemophilia A (SHA) is characterized by spontaneous (non-trauma related) bleeding episodes into the joint space and muscle tissue, leading to progressive joint deterioration and chronic pain. Chronic joint damage is most often associated with severe hemophilia, however more recent research has illustrated that people with moderate hemophilia A (MHA) also experience hemophilic arthropathy and functional impairment. The need to measure joint health in children as well as adults, is underscored by findings from the Joint Outcome Continuation Study, which found that FVIII prophy

Styles APA, Harvard, Vancouver, ISO, etc.

31

Fanale, Michelle A., Nancy L. Bartlett, Andres Forero-Torres, et al. "Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies." Blood 120, no. 21 (2012): 3687. http://dx.doi.org/10.1182/blood.v120.21.3687.3687.

Texte intégral

Résumé :

Abstract Abstract 3687 Background Patients ≥60 years of age comprise a significant portion of the population with hematologic malignancies. In addition, advanced age is a known negative prognostic indicator in many cancers including CD30+ malignancies such as Hodgkin lymphoma (HL) and systemic anaplastic large-cell lymphoma (sALCL). Novel treatments with significant antitumor activity and increased tolerability are needed in this patient population that is often underrepresented in clinical trials. Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate (ADC) comprised of the microtubule

Styles APA, Harvard, Vancouver, ISO, etc.

32

Boardman, Leigh Ann, and Richard H. Yahner. "Wildlife Communities Associated with Even-Aged Reproduction Stands in Two State Forests of Pennsylvania." Northern Journal of Applied Forestry 16, no. 2 (1999): 89–95. http://dx.doi.org/10.1093/njaf/16.2.89.

Texte intégral

Résumé :

Abstract The effects of even-aged forest management on wildlife have been studied extensively in the northeastern United States. The Pennsylvania Bureau of Forestry recently adopted a new forest management practice termed "even-aged reproduction stands with reservation guidelines," hereafter termed EAR stands, which is intended to replace clearcutting as the primary method of even-aged forest management. We examined wildlife communities (breeding birds and small mammals) in 16 stands (8 EAR stands and 8 reference) in central Pennsylvania from February to October 1995. Species richness and abun

Styles APA, Harvard, Vancouver, ISO, etc.

33

Miesbach, Wolfgang A., Giovanni Di Minno, Elena Santagostino, et al. "Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data." Blood 134, Supplement_1 (2019): 1117. http://dx.doi.org/10.1182/blood-2019-128486.

Texte intégral

Résumé :

Background: The availability of factor (F)VIII replacement products has dramatically improved life expectancy for patients with hemophilia A (HA). However, older patients face distinct challenges. Age-related comorbidities such as cardiovascular disease (CVD), often involving treatments that can increase the risk of bleeding, and patients who received treatment before the advent of recombinant products, are more likely to have been exposed to blood-borne viruses carrying chronic infections. It is important to understand clinical outcomes with FVIII products in patients with HA and these comorb

Styles APA, Harvard, Vancouver, ISO, etc.

34

Kumagai, Takashi, Kazunori Murai, Hiroshi Ureshino, et al. "Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial." Blood 138, Supplement 1 (2021): 3601. http://dx.doi.org/10.1182/blood-2021-149483.

Texte intégral

Résumé :

Abstract Introduction: Tyrosine kinase inhibitors (TKIs) dramatically improved the prognosis of chronic myelogenous leukemia (CML), as nearly half of CML patients presenting with a deep molecular response (DMR) over several years could achieve treatment-free remission. DASISION study reported dasatinib (DAS), a second-generation TKI was superior to imatinib to achieve faster and deeper response in treating newly-diagnosed chronic CML. However, standard initial dosage of 100 mg DAS/day might be too potent for patients aged &gt;70 years with CML, possibly owing to the presence of other healt

Styles APA, Harvard, Vancouver, ISO, etc.

35

Palumbo, Antonio, Zdenek Adam, Martin Kropff, et al. "A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015." Blood 118, no. 21 (2011): 475. http://dx.doi.org/10.1182/blood.v118.21.475.475.

Texte intégral

Résumé :

Abstract Abstract 475FN2 Background: An IMiDs® immunomodulatory agent, Len has a dual mechanism of action: its tumoricidal effect directly leads to tumor cell death, and its immunomodulatory effect may keep the tumor in remission. A phase 3, randomized, placebo (Pbo)-controlled trial, MM-015 compares MPR-R with fixed-duration MPR and MP induction in transplant-ineligible NDMM pts. Interim results showed unprecedented reduction in disease progression risk with MPR-R (Palumbo et al, IMW 2011); this analysis focuses on pts aged 65–75 yrs in whom the greatest benefit was observed. Methods: A total

Styles APA, Harvard, Vancouver, ISO, etc.

36

Lozano, Maria Luisa, Maria Eva Mingot-Castellano, María Perera, et al. "Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up." Blood 134, Supplement_1 (2019): 2370. http://dx.doi.org/10.1182/blood-2019-125580.

Texte intégral

Résumé :

Background . In clinical practice, tapering off thrombopoietin receptor agonists (TPO-RA) in immune thrombocytopenia (ITP) is considered if therapy is no longer needed due to a decrease in the disease activity favoring sustained treatment-free responses (TFR). To date, there are no predictors to identify when this approach is likely to be successful, other than earlier start of TPO-RA, and robust platelet responses. Aim. To evaluate clinical predictors of TFR in a real-world cohort of ITP patients treated with TPO-RA by dealing with confounding variables that could be minimized at the stage of

Styles APA, Harvard, Vancouver, ISO, etc.

37

Wei, Andrew, Stephen A. Strickland, Gail J. Roboz, et al. "Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia." Blood 128, no. 22 (2016): 102. http://dx.doi.org/10.1182/blood.v128.22.102.102.

Texte intégral

Résumé :

Abstract Background: Multiple studies have demonstrated the modest efficacy of low-dose cytarabine (LDAC) in older patients (≥65 years) with Acute Myeloid Leukemia(AML) who are unlikely to benefit from an anthracycline and cytarabine intensive induction [CR/CRi rates of 10 - 26%; (CRi = complete remission with incomplete marrow recovery)]. Venetoclax, a selective BCL-2 inhibitor has demonstrated single-agent activity in patients with relapsed and refractory AML [Konopleva et al., ASH 2014]. When administered with LDAC, the recommended phase 2 dose (RP2D) of venetoclax was 600 mg daily [Lin et

Styles APA, Harvard, Vancouver, ISO, etc.

38

Blackberry, Irene, and Nicholas Morris. "The Impact of Population Ageing on Rural Aged Care Needs in Australia: Identifying Projected Gaps in Service Provision by 2032." Geriatrics 8, no. 3 (2023): 47. http://dx.doi.org/10.3390/geriatrics8030047.

Texte intégral

Résumé :

This observational study examines and estimates the trends and impact of population ageing on rural aged care needs in Australia. With its universal health system and subsidised aged care system, Australia is among those countries with a long life expectancy. Being a geographically large country with a relatively small and dispersed population presents challenges for equitable access to aged care service provision. While this is widely acknowledged, there is little empirical evidence to demonstrate the magnitude and location of the aged care service provision gaps in the next decade. We perfor

Styles APA, Harvard, Vancouver, ISO, etc.

39

Kuruvilla, John, Radhakrishnan Ramchandren, Armando Santoro, et al. "Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy." Blood 136, Supplement 1 (2020): 12. http://dx.doi.org/10.1182/blood-2020-142565.

Texte intégral

Résumé :

Introduction: The open-label, international, randomized, phase 3 KEYNOTE-204 (NCT02684292) study showed that in pts with R/R cHL, the PD-1 inhibitor pembro was superior to BV and demonstrated statistically significant, clinically meaningful improvement in PFS, with safety consistent with previous reports. This post hoc exploratory analysis of KEYNOTE-204 evaluated pembro vs BV by number of prior lines of therapy. Methods: Eligible pts were aged ≥18 y, had measurable disease and ECOG PS 0 or 1, and were post−autologous stem cell transplant (auto-SCT) or ineligible for auto-SCT. Pts who were BV-

Styles APA, Harvard, Vancouver, ISO, etc.

40

Jagannath, Sundar, Craig C. Hofmeister, David S. Siegel, et al. "Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis." Blood 120, no. 21 (2012): 450. http://dx.doi.org/10.1182/blood.v120.21.450.450.

Texte intégral

Résumé :

Abstract Abstract 450 Background: New antimyeloma treatments that re-establish tumor response are required to improve survival for pts with advanced, treatment-refractory MM. The MM-002 phase 2 study evaluated the safety and efficacy of oral pomalidomide, in combination with low-dose dexamethasone (POM+LoDex), in pts with relapsed and refractory multiple myeloma (RRMM) who have who have received ≥2 prior therapies including LEN and BORT (Richardson PG, et al. Blood 2011;118:abs 634). Updated results from March 2012 for pts and the outcomes of subgroup analyses are presented. Methods: Eligible

Styles APA, Harvard, Vancouver, ISO, etc.

41

Recher, Christian, Christoph Rollig, Emilie Berard, et al. "Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries." Blood 138, Supplement 1 (2021): 872. http://dx.doi.org/10.1182/blood-2021-147735.

Texte intégral

Résumé :

Abstract The outcome of AML patients (pts) ≥ 70 years is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy (IC) and hypomethylating agents (HMAs). We set up a multicentric European database collecting data of AML pts ≥ 70 y. The primary objective was to compare overall survival in pts selected for IC or HMAs. Individual pt data were collected from 3 European AML registries (DATAML, SAL and PETHEMA). All pts ≥70 y newly diagnosed between 01/01/2007 and 06/30/2018 were included. Variables were age, sex, diagnosis date, AML stat

Styles APA, Harvard, Vancouver, ISO, etc.

42

Navarro, Belén, Juan Manuel Sancho, Silvina Grasso Cicala, Mario Spione, Begoña Soler, and Pier Luigi Zinzani. "Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma (aNHL) an Observational Multicentre Retrospective Study in a Real World Population." Blood 132, Supplement 1 (2018): 1716. http://dx.doi.org/10.1182/blood-2018-99-110784.

Texte intégral

Résumé :

Abstract BACKGROUND: The objective of this study was to evaluate the effectiveness and safety of pixantrone as a rescue treatment for NHL patients in a real world population in Spain and Italy as data on the use of this drug in everyday clinical practice is still scarce. METHODS: The study included patients aged ≥18 years with histologically proven relapsed or refractory B-cell aNHL who were treated according to pixantrone's product information. Primary endpoint was progression-free survival (PFS). Secondary endpoints included the proportion of patients with complete response (CR), partial res

Styles APA, Harvard, Vancouver, ISO, etc.

43

Przespolewski, Amanda, Chetasi Talati, Pankit Vachhani, et al. "Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia." Blood 132, Supplement 1 (2018): 2677. http://dx.doi.org/10.1182/blood-2018-99-113002.

Texte intégral

Résumé :

Abstract Background: Patients (pts) with secondary acute myeloid leukemia (s-AML) have poor long-term outcomes following standard induction chemotherapy with 7+3. Last year, a liposomal cytarabine and daunorubicin formulation (CPX-351) was FDA approved for upfront treatment of s-AML based on a pivotal phase 3 trial demonstrating improved overall survival in pts aged 60-75 years old (Lancet J et al; JCO 2018). Although CPX-351 treatment is indicated in all adults with s-AML, it is unclear whether CPX-351 is safe and effective in younger pts < 60 years. We sought to address this unanswered qu

Styles APA, Harvard, Vancouver, ISO, etc.

44

Gonzalez-Lopez, Tomas Jose, Fernando Fernandez-Fuertes, Maria Cristina Pascual Izquierdo, et al. "Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers." Blood 134, Supplement_1 (2019): 2352. http://dx.doi.org/10.1182/blood-2019-129274.

Texte intégral

Résumé :

Background: Successful discontinuation of eltrombopag in certain immune thrombocytopenia (ITP) patients after complete response has already been demonstrated. However, the frequency of this phenomenon and type of candidate patients are still matter of discussion. Moreover, possibility of long term discontinuation responses is not clearly established. Methods: Here we retrospectively evaluated our whole cohort of 508 adult patients (aged 18 years or more) with primary ITP treated with eltrombopag included in the Spanish Eltrombopag Registry with a focus on the patients who achieved a durable (a

Styles APA, Harvard, Vancouver, ISO, etc.

45

Verschueren, P., J. Avouac, K. Bevers, et al. "AB0191 SAFETY OUTCOMES IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH FILGOTINIB (FIL) IN FILOSOPHY: INTERIM RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1277.1–1277. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1420.

Texte intégral

Résumé :

BackgroundConsideration is needed when using Janus kinase (JAK) inhibitors to treat RA in pts aged ≥65 years or those with cardiovascular (CV) risk factors. The JAK1 preferential inhibitor FIL was generally well tolerated in clinical trials[1]; safety has not been determined in a real-world setting.ObjectivesTo report baseline characteristics and up to 6-month safety data from the first 480 pts treated with FIL in the FILOSOPHY study (NCT04871919), and in two mutually exclusive subgroups based on age and CV risk.MethodsFILOSOPHY is an ongoing, phase 4, non-interventional, European study of pts

Styles APA, Harvard, Vancouver, ISO, etc.

46

Wheeler, Allison P., Miguel A. Escobar, Susan Kearney, et al. "Longitudinal Efficacy and Safety of N8-GP for Prophylaxis and Bleed Control in US Patients." Blood 138, Supplement 1 (2021): 3205. http://dx.doi.org/10.1182/blood-2021-147814.

Texte intégral

Résumé :

Abstract Introduction: N8-GP is an extended half-life recombinant factor VIII product indicated for use in patients with hemophilia A. The pathfinder trials evaluated routine prophylaxis and bleed control in previously treated patients aged ≥12 years (pathfinder2) and patients aged &lt;12 years (pathfinder5), including an extension trial (pathfinder8). The objective of the present analysis was to compare the efficacy and safety of N8-GP in US vs global (including US) patients. Methods: In the pathfinder2 trial, patients aged ≥12 years with severe hemophilia A were administered N8-GP 50 IU/

Styles APA, Harvard, Vancouver, ISO, etc.

47

Zhao, Heng. "Study on the Demographic Analysis of Countries and the Construction of Population Health Index." BCP Business & Management 13 (November 16, 2021): 242–48. http://dx.doi.org/10.54691/bcpbm.v13i.92.

Texte intégral

Résumé :

The data in this paper are from the POPULATION Data Bureau of the United States, Statistics Bureau of the European Union, CEIC global database, etc. SPSS software was used to carry out statistical analysis on the population data of about 230 countries and regions in the world from 2002 to 2012. Through the hierarchical cluster analysis, the population data of the Middle East countries are clustered, and it is found that the population distribution of the Middle East countries is relatively uniform. Multiple linear regression analysis was used to explore the determinants of the total American p

Styles APA, Harvard, Vancouver, ISO, etc.

48

Aletaha, D., R. Westhovens, B. Combe, et al. "POS0676 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 612.2–613. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1563.

Texte intégral

Résumé :

BackgroundFilgotinib (FIL) is a Janus kinase 1 preferential inhibitor for the treatment of moderate to severe rheumatoid arthritis (RA)1. The recommended dose for adults with RA is 200 mg (FIL200); however, a starting dose of 100 mg (FIL100) is recommended for those aged ≥75 years (y) in view of limited clinical experience1. An important consideration is the generally higher incidence of adverse events (AEs) in the elderly due to comorbidities.ObjectivesTo evaluate the efficacy and safety of FIL100 and FIL200 in patients with RA aged ≥75 y.MethodsFINCH 4 (NCT03025308) is an ongoing phase 3 ope

Styles APA, Harvard, Vancouver, ISO, etc.

49

Przespolewski, Amanda, Aaron D. Goldberg, Chetasi Talati, et al. "Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis." Blood 138, Supplement 1 (2021): 1264. http://dx.doi.org/10.1182/blood-2021-153791.

Texte intégral

Résumé :

Abstract Background: Patients (pts) with secondary acute myeloid leukemia (s-AML) have poor long-term outcomes following standard induction chemotherapy with 7+3. In 2017, a liposomal cytarabine and daunorubicin formulation (CPX-351) was FDA approved for upfront treatment of s-AML based on a pivotal phase 3 trial demonstrating improved overall survival in pts aged 60-75 years old (Lancet J et al; JCO 2018). Although CPX-351 treatment was subsequently approved for s-AML regardless of age, data in younger pts &lt; 60 years who were not eligible for the pivotal trial is lacking. We sought to

Styles APA, Harvard, Vancouver, ISO, etc.

50

Seymour, John F., Rena Buckstein, Valeria Santini, et al. "Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study." Blood 128, no. 22 (2016): 2818. http://dx.doi.org/10.1182/blood.v128.22.2818.2818.

Texte intégral

Résumé :

Abstract Background: Patients (pts) aged >65 years (yrs) with AML have a median overall survival (OS) of ~3 months (mos), with worsening OS as age increases: median OS for pts ages 66-75 yrs is ~6 mos, but is only ~2.5 mos for pts ages 76-89 yrs (Walter, Leukemia, 2015). Treatment (Tx) options are limited for these pts, who often have disease features associated with Tx resistance, such as prior hematologic disorders, and a greater risk of Tx-related mortality. With current Tx options, in this setting many physicians or pts do not pursue active AML Tx. The phase 3, randomized AZA-AML-001 st

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!